Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

Exclusion criteria

• . Patients with recalcitrant BP that have never achieved CDA or who have never been in complete disease remission despite long term treatment with super potent topical steroid or oral cotricosteroid
• . Epidermolysis bullosa acquisita, mucous membrane pemphigoid, or anti p200 pemphigoid
• . Mucosal lesions BPDAI score accounts for ≥30% of total BPDAI activity score at randomisation
• . BP considered to be drug induced, in particular diagnosis of BP made within two months of starting a drug well known to induce BP
• . Treatment with BP-directed biologics including: a) Any cell-depleting agents including, but not limited to, rituximab within 12 months prior to baseline, b) Other biologics within five half-lives (if known) or 16 weeks prior to the baseline, whichever is longer, or c) Intravenous immunoglobulin within 16 weeks prior to the baseline.
• . Taking \> 0.3 mg/kg/day OCS at screening
• . Treatment with systemic immunomodulators such as dapsone or doxycycline within four half-lives of the drugs prior to baseline Day 1
• . Treatment with immunosuppressants within the last two weeks prior to baseline